These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12527323)

  • 41. Anthrax toxin: the long and winding road that leads to the kill.
    Abrami L; Reig N; van der Goot FG
    Trends Microbiol; 2005 Feb; 13(2):72-8. PubMed ID: 15680766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polyvalent inhibitors of anthrax toxin that target host receptors.
    Basha S; Rai P; Poon V; Saraph A; Gujraty K; Go MY; Sadacharan S; Frost M; Mogridge J; Kane RS
    Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13509-13. PubMed ID: 16938891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dark sides of capillary morphogenesis gene 2.
    Deuquet J; Lausch E; Superti-Furga A; van der Goot FG
    EMBO J; 2012 Jan; 31(1):3-13. PubMed ID: 22215446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stability of domain 4 of the anthrax toxin protective antigen and the effect of the VWA domain of CMG2 on stability.
    Mamillapalli S; Miyagi M; Bann JG
    Protein Sci; 2017 Feb; 26(2):355-364. PubMed ID: 27874231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple stages of evolutionary change in anthrax toxin receptor expression in humans.
    Choate LA; Barshad G; McMahon PW; Said I; Rice EJ; Munn PR; Lewis JJ; Danko CG
    Nat Commun; 2021 Nov; 12(1):6590. PubMed ID: 34782625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Soluble P-selectin rescues mice from anthrax lethal toxin-induced mortality through PSGL-1 pathway-mediated correction of hemostasis.
    Sun DS; Chang YW; Kau JH; Huang HH; Ho PH; Tzeng YJ; Chang HH
    Virulence; 2017 Oct; 8(7):1216-1228. PubMed ID: 28102766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar.
    Marston CK; Ibrahim H; Lee P; Churchwell G; Gumke M; Stanek D; Gee JE; Boyer AE; Gallegos-Candela M; Barr JR; Li H; Boulay D; Cronin L; Quinn CP; Hoffmaster AR
    PLoS One; 2016; 11(6):e0156987. PubMed ID: 27257909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
    Stiles L; Nelson DJ
    J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.
    Rogers MS; Christensen KA; Birsner AE; Short SM; Wigelsworth DJ; Collier RJ; D'Amato RJ
    Cancer Res; 2007 Oct; 67(20):9980-5. PubMed ID: 17942931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anthrax toxin receptor 1/tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton.
    Werner E; Kowalczyk AP; Faundez V
    J Biol Chem; 2006 Aug; 281(32):23227-36. PubMed ID: 16762926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential dependence on N-glycosylation of anthrax toxin receptors CMG2 and TEM8.
    Friebe S; Deuquet J; van der Goot FG
    PLoS One; 2015; 10(3):e0119864. PubMed ID: 25781883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies in mice reveal a role for anthrax toxin receptors in matrix metalloproteinase function and extracellular matrix homeostasis.
    Reeves C; Charles-Horvath P; Kitajewski J
    Toxins (Basel); 2013 Feb; 5(2):315-26. PubMed ID: 23389402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solid tumor therapy by selectively targeting stromal endothelial cells.
    Liu S; Liu J; Ma Q; Cao L; Fattah RJ; Yu Z; Bugge TH; Finkel T; Leppla SH
    Proc Natl Acad Sci U S A; 2016 Jul; 113(28):E4079-87. PubMed ID: 27357689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
    Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
    Sellman BR; Mourez M; Collier RJ
    Science; 2001 Apr; 292(5517):695-7. PubMed ID: 11326092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anthrax Pathogenesis.
    Moayeri M; Leppla SH; Vrentas C; Pomerantsev AP; Liu S
    Annu Rev Microbiol; 2015; 69():185-208. PubMed ID: 26195305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early interactions between fully virulent Bacillus anthracis and macrophages that influence the balance between spore clearance and development of a lethal infection.
    Cote CK; DiMezzo TL; Banks DJ; France B; Bradley KA; Welkos SL
    Microbes Infect; 2008 May; 10(6):613-9. PubMed ID: 18467145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LRP6 holds the key to the entry of anthrax toxin.
    Bann JG; Cegelski L; Hultgren SJ
    Cell; 2006 Mar; 124(6):1119-21. PubMed ID: 16564002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity.
    Bhatnagar R; Friedlander AM
    Infect Immun; 1994 Jul; 62(7):2958-62. PubMed ID: 8005682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.
    Rogers MS; Cryan LM; Habeshian KA; Bazinet L; Caldwell TP; Ackroyd PC; Christensen KA
    PLoS One; 2012; 7(6):e39911. PubMed ID: 22768167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.